E Jonasch

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology
    Wassim Kassouf
    Division of Urology, McGill University Health Center, Montreal, Quebec, Canada
    J Urol 178:1896-900. 2007
  2. doi request reprint Patterns of intervention for renal lesions in von Hippel-Lindau disease
    Surena F Matin
    Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    BJU Int 102:940-5. 2008
  3. pmc Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma
    Amado J Zurita
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374, Houston, TX 77030 4009, USA
    Cancer 115:2346-54. 2009
  4. pmc Renal cell carcinoma
    Eric Jonasch
    Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    BMJ 349:g4797. 2014
  5. pmc An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays
    Huifang Guo
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Proteome Sci 10:56. 2012
  6. pmc Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease
    E Jonasch
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Ann Oncol 22:2661-6. 2011
  7. doi request reprint Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
    Eric Jonasch
    Department of Genitourinary Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 113:72-7. 2008
  8. pmc Long-term management of patients with metastatic renal cell carcinoma on targeted agents
    Eric Jonasch
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, 77230 1439, USA
    Expert Rev Anticancer Ther 10:1883-9. 2010
  9. doi request reprint Adjuvant and neoadjuvant therapy in renal cell carcinoma
    Eric Jonasch
    UT M D Anderson Cancer Center, Genitourinary Medical Oncology, Houston, TX 77030, USA
    Cancer J 14:315-9. 2008
  10. ncbi request reprint Presurgical therapy in metastatic renal cell carcinoma
    Eric Jonasch
    UT MD Anderson Cancer Center, GU Medical Oncology, Unit 1374, PO Box 301439, Houston, TX 77230 1439, USA
    Expert Rev Anticancer Ther 7:73-8. 2007

Detail Information

Publications71

  1. ncbi request reprint Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology
    Wassim Kassouf
    Division of Urology, McGill University Health Center, Montreal, Quebec, Canada
    J Urol 178:1896-900. 2007
    ..D. Anderson Cancer Center. We compared the outcomes with those in patients with clear cell metastatic renal cell carcinoma...
  2. doi request reprint Patterns of intervention for renal lesions in von Hippel-Lindau disease
    Surena F Matin
    Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    BJU Int 102:940-5. 2008
    ..To review the records of patients at our centre with von Hippel-Lindau (VHL) disease, to determine the incidence of renal cell carcinoma (RCC) and patterns of intervention using minimally invasive therapies...
  3. pmc Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma
    Amado J Zurita
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374, Houston, TX 77030 4009, USA
    Cancer 115:2346-54. 2009
    ..Further preclinical and translational validation studies are still needed to determine their practical utility in the clinical setting...
  4. pmc Renal cell carcinoma
    Eric Jonasch
    Department of GU Medical Oncology, MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    BMJ 349:g4797. 2014
    ..The review concludes with an introduction to the exciting new class of immunomodulatory agents that are currently in clinical trials and may form the basis of a new therapeutic approach for patients with advanced RCC. ..
  5. pmc An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays
    Huifang Guo
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Proteome Sci 10:56. 2012
    ..We developed and optimized an efficient and reproducible procedure for extraction of proteins from FFPE cells and xenografts, and then applied the method to FFPE patient tissues and evaluated its performance on RPPA...
  6. pmc Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease
    E Jonasch
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Ann Oncol 22:2661-6. 2011
    ..Von Hippel-Lindau (VHL) disease induces vascular neoplasms in multiple organs. We evaluated the safety and efficacy of sunitinib in VHL patients and examined the expression of candidate receptors in archived tissue...
  7. doi request reprint Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
    Eric Jonasch
    Department of Genitourinary Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 113:72-7. 2008
    ..The purpose of the current study was to evaluate the activity and safety of TLF in patients with refractory metastatic renal cell carcinoma (RCC)...
  8. pmc Long-term management of patients with metastatic renal cell carcinoma on targeted agents
    Eric Jonasch
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, 77230 1439, USA
    Expert Rev Anticancer Ther 10:1883-9. 2010
    ..As treatment efficacy improves, the optimal integration of systemic therapy, surgery and toxicity management will become a critical aspect of our care for patients with metastatic renal cell carcinoma...
  9. doi request reprint Adjuvant and neoadjuvant therapy in renal cell carcinoma
    Eric Jonasch
    UT M D Anderson Cancer Center, Genitourinary Medical Oncology, Houston, TX 77030, USA
    Cancer J 14:315-9. 2008
    ..Additional questions arise about timing or therapy in the high risk setting. If an effective treatment exists, should it be given before or after nephrectomy? Potential strategies to answer these questions are outlined in the manuscript...
  10. ncbi request reprint Presurgical therapy in metastatic renal cell carcinoma
    Eric Jonasch
    UT MD Anderson Cancer Center, GU Medical Oncology, Unit 1374, PO Box 301439, Houston, TX 77230 1439, USA
    Expert Rev Anticancer Ther 7:73-8. 2007
    ....
  11. pmc Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre
    Eric Jonasch
    Genitourinary Medical Oncology Clinical Pharmacy Services, Division of Pharmacy, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    BJU Int 107:741-7. 2011
    ..To investigate the effect of combining gemcitabine plus capecitabine (GX) with bevacizumab (A) in patients with metastatic RCC previously treated with cytokines and targeted agents...
  12. pmc Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma
    Eric Jonasch
    Department ofGenitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 27:4076-81. 2009
    ....
  13. pmc Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis
    Eric Jonasch
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:57-65. 2010
    ..The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low-dose interferon-alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC)...
  14. doi request reprint Targeted therapy for locally advanced renal cell carcinoma
    Eric Jonasch
    The University of Texas M D Anderson Cancer Center, GU Medical Oncology Unit 1374, PO Box 301439, Houston, TX 77230 1439, USA
    Target Oncol 5:113-8. 2010
    ..Future trials using agents with optimized cytoreductive capabilities in conjunction with therapies capable of preventing metastatic dissemination may improve the outcomes of patients with locally advanced renal cell carcinoma...
  15. pmc Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings
    E Jonasch
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374, Houston, Texas 77030, USA
    Br J Cancer 98:1336-41. 2008
    ..Treatment with vitespen did not result in a discernable benefit in the majority of patients with metastatic RCC treated in this study. Use in combination with immunoregulatory agents may enhance the efficacy of vitespen...
  16. doi request reprint Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma
    Vitaly Margulis
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 180:94-8. 2008
    ....
  17. pmc Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
    L Zhou
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncogene 35:2687-97. 2016
    ..The inhibition of AXL and MET activity may overcome resistance induced by prolonged sunitinib therapy in metastatic RCC. ..
  18. pmc Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy
    S L Richey
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, TX, USA
    Ann Oncol 22:1048-53. 2011
    ..Historically, median overall survival (OS) of patients treated with interferon alpha (IFN-α) without CN was 7.8 months. Median OS in patients treated with targeted therapy (TT) without CN is unknown...
  19. ncbi request reprint A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC)
    J Heymach
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 27:5114. 2009
    ..SR plus interferon (IFN) to assess whether combination therapy improved PFS. Both treatment arms showed similar outcomes (Tannir et al, ASCO. 2008). Here we investigated predictive and prognostic biomarkers in plasma...
  20. pmc A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma
    A J Zurita
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 23:46-52. 2012
    ..We aimed to link the CAF profile to PFS and select candidate predictive and prognostic markers for further study...
  21. pmc Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma
    D Tsavachidou-Fenner
    Department of Systems Biology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 21:1599-606. 2010
    ..Metastatic renal cell carcinoma (mRCC) patients treated with anti-vascular endothelial growth factor (VEGF) therapies demonstrate promising outcomes but not all patients benefit. Factors that predict response remain to be elucidated...
  22. ncbi request reprint Long-term survival of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN)
    S L Richey
    University of Texas M D Anderson Cancer Center, Houston, TX University of Texas Health Science Center at Houston, Houston, TX
    J Clin Oncol 29:346. 2011
    ..We report here outcome data on pts who survived > 24 months (mos)...
  23. ncbi request reprint Treatment of VHL patients with sunitinib: Clinical observations and translational studies
    S F Matin
    University of Texas M D Anderson Cancer Center, Houston, TX Apocell, Inc, Houston, TX
    J Clin Oncol 27:e22047. 2009
    ..Surgical intervention is the treatment of choice. Effective, safe systemic therapy will greatly improve the quality of life of these individuals...
  24. ncbi request reprint A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis
    N M Tannir
    University of Texas M D Anderson Cancer Center, Houston, TX National Cancer Institute, Bethesda, MD
    J Clin Oncol 26:5093. 2008
    ..Therefore, we sought to evaluate the benefit and toxicity of sorafenib plus low-dose (LD) IFN- α in mRCC. In addition, we assessed the ability of plasma and serum biomarkers to correlate with outcome...
  25. ncbi request reprint Phase II presurgical study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma
    E Jonasch
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 27:5004. 2009
    ..The current study was designed to answer these clinical questions, and to define predictive tissue biomarkers using nephrectomy specimens from patients on trial...
  26. pmc Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival
    A J Montero
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 20:1682-7. 2009
    ..To correlate serum cytokine and angiogenic factor (CAF) levels with overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with interferon-alpha (IFN-alpha)...
  27. ncbi request reprint Patterns of progression in renal cell carcinoma: antivascular therapy compared with interferon
    J C Araujo
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 26:5106. 2008
    ..We sought to investigate differences in patterns of progression between patients treated with these two modalities...
  28. ncbi request reprint Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy without cytoreductive nephrectomy (CN)
    S L Richey
    M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 27:e16035. 2009
    ..8 months (mos) [Flanigan et al. Journal of Urology 2004]. The median OS time for pts with mRCC treated with TT sequentially without CN is unknown...
  29. ncbi request reprint Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): A phase II study
    E R Plimack
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 26:5112. 2008
    ..5112 Background: Sunitinib has been shown to produce high response rates (RR) with improved progression-free survival (PFS) in pts with clear-cell RCC (cc-RCC). Retrospective data suggest sunitinib may be effective in ncc-RCC...
  30. pmc Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function
    P German
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncogene 35:4973-80. 2016
    ..Our study reveals a novel mechanism regulating VHL proteostasis and function, which is significant for identifying new drug targets and developing new therapeutic approaches targeting VHL deficiency in VHL diseases. ..
  31. pmc Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies
    M R Matrana
    Hematology and Medical Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Eur J Cancer 49:3169-75. 2013
    ..Outcomes and safety data with pazopanib after targeted therapy (TT) are limited...
  32. ncbi request reprint Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes
    Alan Rodney
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:2143-7. 2006
    ..The secondary objective was to evaluate the safety and tolerability of the combination of capecitabine and gemcitabine in these patients...
  33. ncbi request reprint Metastatic renal cell carcinoma treated with pazopanib after progression on other targeted agents: A single-institution experience
    M R Matrana
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 29:351. 2011
    ..No data has been reported about pazopanib salvage therapy after treatment with other targeted agents...
  34. ncbi request reprint Presurgical bevacizumab in patients with metastatic clear cell renal cell carcinoma: A phase II study
    E Jonasch
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 26:5104. 2008
    ..We initiated a phase II trial to evaluate the safety and efficacy of presurgical bevacizumab (bev) in newly diagnosed patients (pts) with mRCC, with the hope of improving clinical outcomes and to obtain tissue for correlative studies...
  35. pmc Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules
    H Guo
    Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncogene 33:3463-72. 2014
    ....
  36. ncbi request reprint Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
    Naoto T Ueno
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 448, Houston, TX 77030, USA
    Blood 102:3829-36. 2003
    ..It induces rapid complete donor chimerism without the need for donor lymphocyte infusion. Tumor regression associated with GVHD is consistent with graft-versus-tumor effect...
  37. pmc A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents
    Nizar M Tannir
    Genitourinary Medical Oncology Department, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 180:867-72; discussion 872. 2008
    ..We assessed the clinical activity and safety of gemcitabine plus capecitabine in patients with metastatic renal cell cancer previously treated with immunotherapy...
  38. ncbi request reprint Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors
    Vitaly Margulis
    Department of Urology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 10:253-8. 2008
    ..Until then, debulking surgery, which provides a survival benefit for select patients with mRCC, should continue to be used in patients before or after targeted systemic therapy...
  39. pmc Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma
    Vitaly Margulis
    Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 73:337-41. 2009
    ..To evaluate the effect of adjuvant thalidomide on recurrence-free survival (RFS) after nephrectomy for high-risk metastatic renal cell carcinoma (RCC)...
  40. doi request reprint Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors
    Camilo Jimenez
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 435, The University of Texas M D Anderson Cancer, Center, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 94:386-91. 2009
    ..von Hippel-Lindau disease is characterized by highly vascularized tumors of multiple organs...
  41. ncbi request reprint Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carci
    Nizar M Tannir
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:2254-61. 2006
    ..In a randomized Phase II trial, the authors tested the hypothesis that twice-daily low-dose IFN is more effective than daily intermediate-dose IFN in patients with metastatic renal cell cancer (MRCC)...
  42. ncbi request reprint Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma
    Nizar Tannir
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer 107:497-505. 2006
    ..The purpose of the study was to evaluate the efficacy and safety of a bone-targeted regimen consisting of zoledronate, thalidomide, and interferon-gamma in patients with renal cell carcinoma and bone metastases...
  43. ncbi request reprint Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes
    Kamran Ahrar
    The Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, 77030 4009, USA
    J Vasc Interv Radiol 16:679-88. 2005
    ..To report the safety, technical success, and effectiveness of percutaneous radiofrequency (RF) ablation for renal tumors...
  44. pmc Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib
    Zita Dubauskas
    Department of Genitourinary Medical Oncology, The University of Texas Health Science Center, Houston, TX 77030, USA
    Clin Genitourin Cancer 7:20-3. 2009
    ..Cutaneous squamous cell carcinoma (SCC) and inflammation of actinic keratosis (AK) were reported in 2 patients treated with sorafenib (Lacouture et al), but the scope of this observation has not been evaluated...
  45. doi request reprint Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease
    Raghunandan Vikram
    Department of Diagnostic Radiology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Radiographics 29:741-54; discussion 755-7. 2009
    ..A mass that enhances to a lesser degree is likely to be a non-clear cell RCC. It is common for metastatic lesions from pRCC to show enhancement characteristics similar to those of the primary tumor and be hypovascular...
  46. ncbi request reprint Everolimus-associated pneumonitis (EAP) in metastatic renal cell cancer patients (mRCC): A single-center experience
    D H Cauley
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 29:332. 2011
    ..The goal of this review was to characterize the incidence, timing, management, and outcomes related to everolimus-associated pneumonitis (EAP)...
  47. doi request reprint A Randomized Phase 2 Study of MK-2206 versus Everolimus in Refractory Renal Cell Carcinoma
    E Jonasch
    Department of Genitourinary Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson, Houston, USA
    Ann Oncol . 2017
    ....
  48. ncbi request reprint Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience
    A Karim Kader
    Department of Urology, University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    J Urol 177:855-60; discussion 860-1. 2007
    ..The benefit in the elderly population (75 years or older) is unclear. We reviewed our experience to help determine if it is of benefit in this patient population...
  49. pmc Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment
    E Jason Abel
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 184:1877-81. 2010
    ..We assessed the accuracy of percutaneous primary tumor biopsy for metastatic renal cell carcinoma by comparing biopsy findings to final nephrectomy pathology in patients undergoing cytoreductive nephrectomy...
  50. pmc Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma
    Jose A Karam
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 184:1882-7. 2010
    ....
  51. ncbi request reprint Treatment of poor-risk metastatic renal carcinoma patients with combination gemcitabine, capecitabine, and bevacizumab at a tertiary cancer center
    L Miller
    University of Texas M D Anderson Cancer Center, Houston, TX University of Houston, Houston, TX
    J Clin Oncol 27:e16112. 2009
    ..These combinations may lead to formal clinical trials. Evaluation of mRCC patients given an empiric combination of gemcitabine (gem) capecitabine (cap), and bevacizumab (bev) at a tertiary care center was performed...
  52. ncbi request reprint Fibroblast growth factor receptor 1 (FGFR1) expression and activation in clear cell renal cell carcinoma (ccRCC)
    T H Ho
    University of Texas M D Anderson Cancer Center, Houston, TX Texas A and M Health Science Center, Houston, TX
    J Clin Oncol 29:e15015. 2011
    ..FGF pathway activation may also provide a compensatory mechanism for angiogenesis in the setting of vascular endothelial growth factor (VEGF) blockade. However, the prognostic impact of FGF pathway activation is unknown in ccRCC...
  53. ncbi request reprint Chromosome 14q imbalances and pathways associated with resistance to antiangiogenic therapy in clear cell renal cell carcinoma
    E Jonasch
    University of Texas M D Anderson Cancer Center, Houston, TX The Methodist Hospital Research Institute, Houston, TX
    J Clin Oncol 29:339. 2011
    ..The HIF1 alpha gene is located on chromosome 14q. In this study, the goal was to determine whether chromosomal imbalances identified with SNP arrays are linked to HIF ratios, and to clinical outcome...
  54. ncbi request reprint Outcome of patients (pts) with renal medullary carcinoma (RMC) treated in the era of targeted therapies (TT): A multicenter experience
    N M Tannir
    University of Texas M D Anderson Cancer Center, Houston, TX Karmanos Cancer Institute, Wayne State University, Detroit, MI Fox Chase Cancer Center, Philadelphia, PA University of North Carolina at Chapel Hill, Chapel Hill, NC
    J Clin Oncol 29:386. 2011
    ..The primary objectives of this study were to evaluate the clinical characteristics and treatment outcome of RMC pts...
  55. ncbi request reprint Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib: A single institution experience
    Z Dubauskas
    University of Texas M D Anderson Cancer Center, Houston, TX The University of Texas Health Science Center, Houston, TX
    J Clin Oncol 26:16101. 2008
    ..Cutaneous squamous cell carcinoma (SCC) and inflammation of actinic keratosis (AK) were reported in two patients treated with sorafenib (Lacouture et al), but the scope of this observation has not been evaluated...
  56. ncbi request reprint Reverse-phase protein array marker evaluation of protein expression patterns related to anti-angiogenesis treatment in renal cell carcinoma
    D Tsavachidou
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 26:16016. 2008
    ....
  57. pmc Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis
    X D Liu
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncogene 34:2450-60. 2015
    ..This study indicates that autophagy has an anticancer role in ccRCC tumorigenesis, and suggests that constitutive autophagic degradation of HIF2α is a novel tumor suppression mechanism. ..
  58. doi request reprint A novel von Hippel-Lindau point mutation presents as apparently sporadic pheochromocytoma
    Thereasa A Rich
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Invest 26:642-6. 2008
    ..The nearly asymptomatic patient's father also carries the same mutation. Similar to other mutations localized in the same codon, the Gly104Val VHL mutation seems to have an attenuated disease phenotype...
  59. ncbi request reprint Port-site metastasis: the influence of biology
    Ralph A Highshaw
    Department of Urology, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Eur Urol 47:357-60. 2005
    ..We present a case of a pelvic chordoma that metastasized to a prior laparoscopic radical nephrectomy port-site...
  60. doi request reprint Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL
    E Hasanov
    Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A and M Health Science Center, Houston, TX, USA
    Oncogene . 2017
    ..Together, these data identify VHL as an E3 ligase with important cellular functions under both normoxic and hypoxic conditions.Oncogene advance online publication, 23 January 2017; doi:10.1038/onc.2016.495...
  61. ncbi request reprint Survival benefit in bevacizumab-based therapy in sickle cell trait patients diagnosed with renal medullary carcinoma
    E D Johnson
    M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 27:e16096. 2009
    ..In an effort to evaluate treatment outcomes, we retrospectively examined those patients diagnosed with RMC who were treated with and without bevacizumab based regimens...
  62. ncbi request reprint Patient characteristics associated with dose-limiting sunitinib adverse events
    B Atkinson
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 27:e16110. 2009
    ..We sought to identify 1) baseline patient (pt) characteristics that predispose for DM, 2) the most common AEs requiring DM in a non-protocol setting, and 3) the impact of dose limiting AEs on treatment continuation...
  63. ncbi request reprint A randomized phase II study of MK-2206 in comparison with everolimus in refractory renal cell carcinoma.(NCI 8727)
    E Jonasch
    University of Texas M D Anderson Cancer Center, Houston, TX University of California, Davis, Sacramento, CA
    J Clin Oncol 29:TPS192. 2011
    ..This study will randomize patients who progressed on anti-VEGF therapy between MK-2206 and everolimus, a mammalian target of rapamycin inhibitor...
  64. ncbi request reprint Tyrosine kinase inhibitors and development of brain metastasis in metastatic renal cell carcinoma: A retrospective review
    J Verma
    Baylor College of Medicine, Houston, TX University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 29:340. 2011
    ..The purpose of our study is to evaluate the impact of TKIs on incidence of BM and OS in patients with mRCC...
  65. pmc Site-specific activation of AKT protects cells from death induced by glucose deprivation
    M Gao
    1 Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, People s Republic of China 2 Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncogene 33:745-55. 2014
    ....
  66. pmc Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma
    Jinhee Kim
    Department of Carcinogenesis, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 15:81-90. 2009
    ..p27 localization and expression has prognostic and predictive value in cancer. Little is known regarding expression patterns of p27 in renal cell carcinoma (RCC) or how p27 participates in disease progression or response to therapy...
  67. pmc Adjuvant and neoadjuvant therapy in renal cell carcinoma
    Michel Choueiri
    University of California, San Diego, La Jolla, CA 92093, USA
    Curr Clin Pharmacol 6:144-50. 2011
    ..There is optimism that locally advanced RCC might benefit from adjuvant or neoadjuvant treatment with these therapies. Ongoing clinical trials are addressing the role of targeted agents in this disease state...
  68. ncbi request reprint Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis
    Chun Chui Tsao
    Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Biol Ther 7:1619-27. 2008
    ..Compared to Mxi1-proficient tumors, Mxi1-deficient tumors display reduced cellular proliferation. These results establish Mxi1 as an important downstream target of HIF that contributes to pVHL-deficient renal cancer tumorigenesis...
  69. ncbi request reprint Kidney cancer. Clinical practice guidelines in oncology
    Robert J Motzer
    J Natl Compr Canc Netw 4:1072-81. 2006
  70. ncbi request reprint Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience
    Wassim Kassouf
    Department of Urology, McGill University Health Center, Montreal, Quebec, Canada
    Urology 69:835-8. 2007
    ..We reviewed our experience with cytoreductive nephrectomy in patients with contiguous organ involvement (Stage T4NxM1) to evaluate the outcome and morbidity...
  71. ncbi request reprint Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute
    Kenneth A Katz
    Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Melanoma Res 15:77-82. 2005
    ..The demographic and survival characteristics of this MUP cohort mirrored those found in previous studies. More studies of MUP patients, as well as a standardized definition of MUP, may shed light on the pathogenesis and prognosis of MUP...